JNJ Oct 2024 157.500 call
| Previous Close | 4.7000 |
| Open | 2.4400 |
| Bid | 2.3900 |
| Ask | 3.9000 |
| Strike | 157.50 |
| Expire Date | 2024-10-04 |
| Day's Range | 2.4400 - 2.4400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 10 |
Insider MonkeyIs Johnson & Johnson (JNJ) the Best Stock to Buy According to Billionaire Ray Dalio?
We recently compiled a list of the Best Stocks to Buy According to Billionaire Ray Dalio. In this article, we will look at where Johnson & Johnson (NYSE:JNJ) ranks among the best stocks to buy according to billionaire Ray Dalio. Ray Dalio was born in 1949 and graduated from Long Island University in 1971. After […]
BloombergSanofi Healthcare Bidders Revising Offers Over Talc Concerns
(Bloomberg) -- Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder, according to people with knowledge of the matter. Most Read from BloombergWhat Do US Vehicle Regulators Have Against Tiny Cars?Singapore Ends 181 Years of Horse Racing to Make Way for HomesMexico City Restricts Airbnb Rentals to Curb ‘Gentrification’For a Master of Brutalist Provocations, a Modest Museum Apprai
ReutersJ&J discontinues dengue drug study after changes in R&D portfolio
In a separate emailed statement, J&J also said it will also "explore opportunities to advance the clinical development of mosnodenvir outside the company, so that others may build on our research." Six of 10 participants on the drug showed no detectable dengue virus in their blood after being injected with a type of the pathogen, according to data that was presented by J&J in October last year from another mid-stage study. J&J said that efficacy data from the field study will be available once the final data analyses are complete.
